Anti-Wolbachia therapy is a new method of treatment that eradicates the adult worms that can cause filariasis by eliminating bacteria known as Wolbachia that live in the cells of their bodies. As filariae are dependent on these Wolbachia for growth, development, reproduction and survival, these worms can be effectively eradicated by first eliminating the Wolbachia inside them.
Anti-Wolbachia therapy is expected to lead to worm sterility and effective worm eradication, thereby reducing treatment timeframes and providing superior therapeutic outcomes compared to existing anti-filarial drugs. Further, as anti-Wolbachia programs are still in their infancy, this collaboration is expected to potentially provide a unique opportunity to make a significant contribution to communities affected by filariasis.
Eisai has entered into a collaboration with the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of filariasis. Under the collaboration, Eisai will work with LSTM to develop and implement new tools and technologies for the control and treatment of tropical diseases, and the University of Liverpool to identify and develop novel drug candidates that efficiently eliminate the bacteria Wolbachia. The Global Health Innovative Technology (GHIT) Fund awarded the project at $1.09 million grant in 2014.
|Value||USD 1.09 Million|